Conversely, several YAP/TAZ inhibitory strategies have proven effective at decreasing atherosclerosis burden in Apoe–/– mice, including morpholino oligonucleotides that systemically blunt YAP/TAZ activity, systemic TAZ knockdown with short hairpin RNAs, and EC-specific CRISPR/Cas9–mediated YAP reduction (20, 21). The gene discussed is APOE; the disease is atherosclerosis.